Key result
Individualized medical therapy for pediatric patients with recurrent syncope and asystole during tilt testing prevented recurrent syncope in 78% of patients over a median 31-month follow-up.
Why the study?
Does individualized medical therapy prevent recurrent syncope in pediatric patients with cardioinhibitory syncope?
Observational (n=18)
Does individualized medical therapy prevent recurrent syncope in pediatric patients with cardioinhibitory syncope?
Pharmacological therapy appears safe and effective for managing recurrent syncope with asystole in young patients, potentially avoiding the need for pacemaker implantation.
Answers are grounded in this paper and cite their sources.
May support pacing avoidance in pediatric cardioinhibitory syncope; hypothesis-generating and requires randomized confirmation.
A small percentage of pediatric patients with neurally mediated syncope will have an asystolic response during upright tilt table testing. The purpose of this study is to evaluate the incidence of asystole during tilt table testing, and to assess the outcome of medical management of such patients. Of 398 patients undergoing evaluation for recurrent syncope between January 1989 and 1994, 18 (4.5%) experienced asystole lasting > or = 5 seconds during baseline tilt test. Patients had experienced a mean of four episodes of syncope, with a mean age at the time of tilt test of 11.1 +/- 4.0 years. The median duration of asystole was 10 seconds (range 5-40 s). Treatment was individualized to increased fluids and salt intake (3 patients), metoprolol (8 patients), pseudoephedrine (4 patients), disopyramide (1 patient), or combination therapy with fludrohydrocortisone (2 patients). During a median duration of follow-up of 31 months, no additional syncope was experienced by 78% of patients. Recurrent syncope in 4 patients was associated with either noncompliance or discontinuation of therapy in 3 patients; in 1 patient, increasing the dose of metoprolol was effective in preventing recurrences. We conclude that young patients with recurrent syncope and asystole during tilt test may be safely and effectively managed with pharmacological therapy, without resorting to pacemaker implantation.
No takes yet. Share an insight, caveat, or question.
Deal et al. (1997) conducted an observational in Recurrent syncope with asystole (n=18). Medical management was evaluated on Freedom from recurrent syncope. Individualized medical therapy for pediatric patients with recurrent syncope and asystole during tilt testing prevented recurrent syncope in 78% of patients over a median 31-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: